Jasper Therapeutics, Inc.

Snapshot

Jasper is a pre-revenue clinical-stage biotech that lost $75.8M in FY 2025 and burned $77.2M in free cash flow, against $28.7M in cash on hand. Share count jumped 31% YoY even before a July 2026 all-stock merger with Kira Pharmaceuticals that will leave legacy shareholders with only about 6.68% of the combined company.

What's Happening Right Now

• Mon 31st Aug '26 · Annual meeting: At its July 31, 2026 annual meeting, Jasper shareholders elected two directors, ratified PricewaterhouseCoopers as auditor, and approved executive pay with strong support and no contested items.
• Mon 24th Aug '26 · CVR: Jasper confirmed shareholders of record on July 16, 2026 received Contingent Value Rights tied to a possible $30 million payment if the FDA grants a priority review voucher for briquilimab by the end of 2028.
• Fri 14th Aug '26 · Earnings: In its Q2 2026 update, Jasper said the Kira deal and $132M PIPE financing give the combined company capital to fund operations through the second half of 2028, while reporting a quarterly net loss of $2.8 million.
• Wed 22nd Jul '26 · Merger: Jasper completed an all-stock acquisition of Kira Pharmaceuticals and closed a $132M private placement; legacy Jasper shareholders will retain only about 6.68% of the combined company, which will have roughly 653.6 million shares outstanding.
• Mon 20th Jul '26 · Offering: Raised $132.00M in gross proceeds through a private placement (PIPE).
• Thu 16th Jul '26 · Offering: Closed an offering. Proceeds are not disclosed in the filings reviewed.
• Tue 9th Jun '26 · Delisting notice: Nasdaq notified Jasper on June 3, 2026 that its stock failed to maintain the $1.00 minimum bid price for 30 straight days, giving the company until November 30, 2026 to regain compliance or face possible delisting.
• Wed 31st Dec '25 · ATM sale: Sold 1.23M shares through its at-the-market program.